Adaptive Biotechnologies (ADPT) Q2 2026 earnings review
MRD Growth Engine Masks Optical Net Loss as Company Prepares to Split
Adaptive delivered a robust second quarter, driven by its core Minimal Residual Disease (MRD) business. clonoSEQ test volumes grew a staggering 43% YoY, pushing total revenue up 22%. However, the optical Net Loss widened 56% YoY to $39.9 million. This was entirely due to a $23.7 million one-time charge to extinguish the OrbiMed royalty liability, funded by a new $345 million convertible note. With the balance sheet cleaned up and MRD operating profitably, management dropped the biggest news of the quarter: a planned strategic separation of the cash-burning Immune Medicine business from the highly profitable MRD segment. Following the strong quarter, management raised full-year MRD revenue guidance and lowered OpEx targets.
🐂 Bull Case
Shedding the Immune Medicine business will immediately transform Adaptive's consolidated financial profile. The MRD segment generated $9.1 million in Adjusted EBITDA this quarter, while Immune Medicine acted as a $6.3 million drag.
Test volumes are accelerating aggressively, up 43% YoY to 36,111 tests. This proves the company's EMR integration and community penetration strategies are yielding sustainable, compounding growth.
🐻 Bear Case
The Immune Medicine unit saw revenue plunge 40% YoY to just $5.4 million. While management intends to spin it off, the deteriorating top-line makes it a potentially difficult asset to monetize or offload favorably.
The issuance of $345 million in zero-coupon convertible notes replaces a pure royalty liability with potential equity dilution, which could cap upside for current shareholders if the stock runs.
⚖️ Verdict: 🟢
Bullish. The optical widening of the net loss hides excellent operational execution. The core MRD business is scaling profitably, the cap structure is now unburdened from the OrbiMed royalty, and the planned separation of the cash-burning Immune Medicine segment removes a persistent overhang.
Key Themes
Strategic Separation of Business Units
The defining announcement of the quarter is the planned separation of the MRD and Immune Medicine businesses. This explains the recent balance sheet maneuvers and the transition of co-founder Harlan Robins to a consultant role. The divergence in segment performance clearly justifies this move: MRD is a high-growth, profitable diagnostic engine, while Immune Medicine is a data/therapeutic discovery platform requiring different capital structures and timelines.
clonoSEQ Volume Acceleration
Clinical volume remains the core growth engine. Q2 delivered 36,111 tests, representing a 43% YoY acceleration (faster than the 41% YoY growth seen in Q1). Management's prior stated focus on shifting to blood-based testing and driving community penetration via technology integrations is clearly converting into sustainable demand.
Cap Structure Clean-Up Enables Separation
Adaptive completed a $345 million zero-coupon convertible senior notes offering and immediately used funds to repay the OrbiMed Purchase Agreement. While this triggered a $23.7 million extinguishment loss in the quarter, eliminating the royalty burden was a necessary prerequisite for separating the MRD business into an attractive standalone entity with clean cash flows.
EMR Integration as a Competitive Moat
Though not explicitly updated in the Q2 press release, the 43% volume surge heavily validates the company's technology infrastructure strategy. Deep integration with Epic and Flatiron's OncoEMR allows for automated serial testing orders, embedding clonoSEQ directly into community clinician workflows and creating high switching costs against emerging flow-cytometry competitors.
Sequential Revenue Dip in MRD Contradicts Volume Narrative
Despite a massive 43% YoY increase in test volumes, total MRD revenue actually declined sequentially from $67.1M in 26Q1 to $66.2M in 26Q2. This data point contradicts the pure growth narrative. The likely explanation is that Q1 included $9.0M in lumpy biopharma milestones (which management warned about previously), while Q2 did not. Investors must recognize that while clinical volume is soaring, total MRD revenue remains subject to quarter-to-quarter volatility based on trial readouts.
Immune Medicine Segment Deterioration
Immune Medicine revenue plummeted 40% YoY to $5.4 million. Even adjusting for the lack of Genentech revenue (which terminated last year), core segment growth was an anemic 8%. With an Adjusted EBITDA loss of $6.3M for the quarter, the segment continues to burn cash. The success of the upcoming business separation hinges on finding external funding or a buyer for this deteriorating asset.
Optical Net Loss Widening
Total Net Loss widened from $25.6M in 25Q2 to $39.9M in 26Q2. While management rightly points out that excluding the OrbiMed debt extinguishment, the loss was only $16.2M, the headline numbers remain messy. This kind of financial engineering and one-off adjustments can exhaust retail investors trying to track true operating leverage.
Other KPIs
Decelerating growth. Up only 4% YoY compared to the 22% top-line revenue growth, demonstrating strict cost discipline and the realization of operational leverage from the NovaSeq X Plus platform implementation.
Significantly up from $240M at the end of Q1, bolstered entirely by the $345 million convertible notes offering, providing ample liquidity to execute the business separation.
Stable profitability profile. Up drastically from $1.9M in the prior year, marking the fifth consecutive quarter of segment profitability, proving the MRD unit is self-sustaining.
Guidance
Accelerating. Raised from previous guidance of $260 - $270 million. The new midpoint ($273M) implies robust annual growth of ~28% over FY25's $212.3 million. This reflects soaring confidence in clinical volume pull-through.
Decelerating. Lowered from prior guidance of $350 - $360 million. Achieving higher top-line revenue while simultaneously lowering OpEx expectations is the ultimate signal of operating leverage.
Key Questions
Structure and Timing of the Business Separation
With the announcement of the intended separation of the MRD and Immune Medicine businesses, what is the expected timeline and structure? Are you leaning toward a tax-free spin-off, a direct sale, or winding down certain discovery programs?
Capital Allocation Post-Separation
How much of the newly fortified $371.7M cash balance and the $345M convertible debt obligation will be apportioned to the standalone MRD business versus the Immune Medicine unit?
Sequential MRD Revenue Dynamics
MRD test volumes grew aggressively in Q2, yet MRD segment revenue was slightly down sequentially from Q1. Can you confirm if this was entirely due to the absence of Q1's $9M biopharma milestones, and should we model further lumpiness in H2?
Competitive Response in Pricing
As test volumes scale, what is the status of your previously stated goal to push U.S. ASP toward $1,400? Have recent competitive noise or payer negotiations capped pricing leverage?